Fig. 1 · Structure

Documents & Downloads

Digoxin

Cat. No. A14242 CAS 20830-75-5

sodium-potassium pump inhibitor

Digoxin is a sodium-potassium pump inhibitor.

In Stock

Publications for Digoxin

2 publications citing this product

  1. Ella Martin, .et al. , ACS Pharmacol Transl Sci, 2025, May 12;8(9):2996-3006 PMID: 40969890
  2. Reiko Watanabe, .et al. , J Med Chem, 2021, Mar 11;64(5):2725-2738 PMID: 33619967

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Digoxin binds directly to Na,K-ATPase. A pig kidney enzyme structure places it in the extracellular ion-pathway cavity, with its sugar chain directed outward. In purified human Na,K-ATPase assays, reported Ki values were 268 ± 13.8 nM for α1β1, 58.7 ± 5.4 nM for α2β1 and 42.8 ± 3.0 nM for α2β3 (means ± SEM). These values depend on assay conditions, including potassium, and are not cellular IC50 values. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Sodium channel

Digoxin Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Digoxin from 2 published references. In vitro models include purified pig kidney Na+,K+-ATPase α1β1γ stabilized in the E2P state.

Digoxin In Vitro Studies

Digoxin-bound pig kidney Na,K-ATPase structure

Biochemical assay · Purified pig kidney Na+,K+-ATPase α1β1γ stabilized in the E2P state [1]

The crystallographic model places digoxin in the extracellular ion-pathway cavity formed by transmembrane segments αM1–6. The steroid/lactone region extends toward the cation sites and the trisaccharide points toward the extracellular environment. This supports direct pump binding; it does not establish cellular potency or clinical efficacy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Location of bound digoxin in the Na,K-ATPase complexX-ray crystallographic binding-site assignment Extracellular ion-pathway cavity formed by αM1–6[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.5 mM digoxin during preparation of the E2P–digoxin complex
Method
Preincubation of enzyme membrane fraction followed by detergent solubilization and crystallization
Reported limits
Preincubation duration and digoxin stock solvent were not specified in the read main-text crystallization method. This concentration is a structural preparation condition.
Methods and source locations

Compound reported in the paper: Digoxin; Compound label in the paper: Digoxin (E2P–digoxin complex)

Compound-level binding evidence from pig kidney enzyme; no supplier-lot equivalence inferred.

Figures 1–2; Results and Discussion; Crystallization and Data Collection; Structure Determination and Refinement

Location of bound digoxin in the Na,K-ATPase complex: X-ray diffraction with molecular replacement and restrained refinement; digoxin and comparative bufalin structures; previously determined ouabain-bound complex used for comparison. — Results and Discussion, structural interpretation; Figures 1C, 1E–F and 2A; Structure Determination and Refinement

Inhibition of purified human Na,K-ATPase isoforms

Biochemical assay · Purified detergent-soluble human α1β1, α2β1 and α2β3 Na,K-ATPase complexes reconstituted with FXYD1 [2]

Digoxin inhibited all three tested human isoform complexes. Reported Ki values were lower for α2-containing complexes under these assay conditions. Potassium antagonism affects apparent isoform selectivity, so these values should not be generalized to other assay media or intact cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of human α1β1 Na,K-ATPase activityKi (nM; mean ± SEM) 268 ± 13.8 nM[2]
Inhibition of human α2β1 Na,K-ATPase activityKi (nM; mean ± SEM) 58.7 ± 5.4 nM[2]
Inhibition of human α2β3 Na,K-ATPase activityKi (nM; mean ± SEM) 42.8 ± 3.0 nM[2]

Literature-Reported Treatment Conditions

Treatment concentration
Digoxin concentration series; the exact parent-digoxin range is not specified in Table 1 or the main assay method.
Exposure duration
ATPase activity measured over 1 h
Method
37 °C ATPase activity assay; phosphate detected with PiColorLock gold malachite green. Results discussion specifies 5 mM K+ in the reaction medium.
Reported limits
Digoxin stock solvent and exact concentration-series bounds are not specified in the read main assay method. Ki is the reported inhibition parameter, not a treatment dose or a cellular IC50.
Methods and source locations

Compound reported in the paper: Digoxin; Compound label in the paper: Digoxin, Sigma D6003

Digoxin-level purified human enzyme results; no Adooq lot validation.

Table 1; Identification of Digoxin Derivatives with Selectivity for the α2β3 Isoform Complex; Methods: Chemicals and Expression, Purification, and Activity of Human Na,K-ATPase Isoforms

Inhibition of human α1β1 Na,K-ATPase activity: Purified human α1β1 with FXYD1; ATPase phosphate-release inhibition assay; 3–5 experiments per methods (exact n for this entry not separately given). — Table 1, Digoxin row, α1β1 column; Methods: Expression, Purification, and Activity of Human Na,K-ATPase Isoforms

Inhibition of human α2β1 Na,K-ATPase activity: Purified human α2β1 with FXYD1; ATPase phosphate-release inhibition assay; 3–5 experiments per methods (exact n for this entry not separately given). — Table 1, Digoxin row, α2β1 column; Methods: Expression, Purification, and Activity of Human Na,K-ATPase Isoforms

Inhibition of human α2β3 Na,K-ATPase activity: Purified human α2β3 with FXYD1; ATPase phosphate-release inhibition assay; 3–5 experiments per methods (exact n for this entry not separately given). — Table 1, Digoxin row, α2β3 column; Methods: Expression, Purification, and Activity of Human Na,K-ATPase Isoforms

Digoxin In Vivo Studies

In a small rabbit experiment, one topical drop of 1 mM digoxin did not lower basal intraocular pressure over 4–5 h. The right eye received digoxin and the left eye PBS; Figure 4A reports means ± SEM for three rabbits. This negative result is specific to the tested acute topical conditions. [2]

Topical digoxin did not lower basal rabbit intraocular pressure

Animal study · New Zealand white rabbits, 3–3.5 kg, approximately 1 year old; either sex; three rabbits in the digoxin experiment [2]

A single topical application of parent digoxin did not reduce basal intraocular pressure over the reported 4–5 h observation period. The favorable results for modified digoxin derivatives in this paper do not apply to parent digoxin.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Basal intraocular pressure normalized to time-zero IOPIOP/IOP at t = 0 No reduction of basal IOP reported for digoxin over 4–5 h; n = 3 rabbits, plotted means ± SEM[2]

Conditions shared by the study groups

Route
Topical ocular
Frequency
Once at time 0
Treatment course
4–5 h observation
Vehicle
Contralateral eye: one drop PBS
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Digoxin with contralateral PBS control
One drop of 1 mM digoxin to the right eye
Left eye received PBS in the same rabbitParent digoxin did not lower basal IOP; Figure 4A shows normalized IOP means ± SEM for three rabbits.[2]
Digoxin with contralateral PBS control
Model: Three New Zealand white rabbits; basal IOP
Reported limits: Drop volume, individual animal sex assignments, and a formal equivalence margin are not given in the read protocol.
Methods and source locations

Compound reported in the paper: Digoxin; Compound label in the paper: Parent digoxin comparator

Acute negative ocular result in rabbits under the tested topical conditions; no inference about other routes or human efficacy.

Figure 4A and caption; basal IOP Results; Methods: Chemicals and IOP Measurements

Basal intraocular pressure normalized to time-zero IOP: Pneumatonometry; digoxin-treated right eye compared with PBS-treated left eye. No exact effect size or formal equivalence margin extracted from curves. — Figure 4A and caption; basal-IOP paragraph immediately preceding Figure 4; Methods: IOP Measurements

Digoxin with contralateral PBS control · Figure 4A and caption; basal IOP Results; Methods: IOP Measurements

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 20830-75-5
Applications sodium-potassium pump inhibitor
Formula C41H64O14
Molecular Weight 780.94
SMILES
C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 96 mg/mL (122.93 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
1 mg/mL
Vehicle
2% DMSO+corn oil

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Digoxin Research References

  1. [1] Laursen M, Gregersen JL, Yatime L, et al. Structures and characterization of digoxin- and bufalin-bound Na+,K+-ATPase compared with the ouabain-bound complex Proceedings of the National Academy of Sciences of the United States of America (2015). PMID: 25624492 DOI: 10.1073/pnas.1422997112 Source material
  2. [2] Katz A, Tal DM, Heller D, et al. Digoxin derivatives with selectivity for the α2β3 isoform of Na,K-ATPase potently reduce intraocular pressure Proceedings of the National Academy of Sciences of the United States of America (2015). PMID: 26483500 DOI: 10.1073/pnas.1514569112 Source material

Publications

2 publications citing this product

  1. Ella Martin, .et al. , ACS Pharmacol Transl Sci, 2025, May 12;8(9):2996-3006 PMID: 40969890
  2. Reiko Watanabe, .et al. , J Med Chem, 2021, Mar 11;64(5):2725-2738 PMID: 33619967

Added to your cart

View Cart Checkout
Loading...